cellectis.com rapport :   Visitez le site

Données techniques du cellectis.com

Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte cellectis.com.Actuellement, hébergé dans France et son fournisseur de services est Celeste .

the related websites

tradingsat.com zonebourse.com boursier.com boursorama.com boursedirect.fr abcbourse.com mecateamcluster.org assu2000.fr ldrc.ca nestle.fr needsandmoods.com senat.fr bluebamboofengshui.com 

Analyse d'en-tête HTTP

Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé nginx/1.6.2 contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.

DNS

HtmlToText

-- about research products investors press agenda fr next-generation car t-cells to cure cancer gene edited off-the-shelf immunotherapies: a future-defining shift in simplicity, availability, and cost-effectiveness learn more watch the video talen® enables gene editing at industrial scale gene editing will completely reshape molecular medicine within five years. our flagship talen® technology provides us with the ability to rethink how we treat diseases altogether. cells can be engineered with optimized features for cancer therapies, drug discovery, gene function studies, industrial biotechnology and more. it is the next transformative step in medicine. learn more "off-the-shelf" immunotherapies that can work for the largest number of patients cellectis gene-edits “chimeric antigen receptor” (car) t-cells from healthy donors into “off-the-shelf” immunotherapy product candidates that are designed to work for the largest number of patients. it’s the difference between being an off-the-shelf product and a service in which each treatment has to be custom-made. this same technology, developed by cellectis, could help in designing therapies for many other diseases. learn more strong intellectual property, global strategic partnerships. 18 years of innovation. 175 patent families. 163 granted patents and 737 applications. global strategic partnerships with allogene, servier, and leading universities all over the world. learn more editing life press cellectis appoints stefan scherer m.d., ph.d., as senior vice president clinical development and deputy chief medical officer published on: august 02, 2018, 16:30 e.s.t. cellectis reports financial results for 2nd quarter and first six months 2018 published on: august 01, 2018, 16:30 e.s.t. cellectis publishes novel methods to improve the clinical use of chimeric antigen receptor t-cell therapy in scientific reports published on: june 12, 2018, 16:30 e.s.t. fda grants cellectis ind approval for ucart22 in b-all published on: june 04, 2018, 16:30 e.s.t. cellectis appoints stefan scherer m.d., ph.d., as senior vice president clinical development and deputy chief medical officer august 2 nd , 2018 – new york (n.y.) – cellectis (euronext growth: alcls - nasdaq: clls), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic car t-cells (ucart), announced today the appointment of dr. stefan scherer, m.d., ph.d., to the role of senior vice president clinical development and deputy chief medical officer. dr. scherer joins cellectis from novartis pharmaceuticals corporation, where he was the head of early development, strategy and innovation for u.s. oncology. dr. scherer is based in new york and will report to prof. stéphane depil, m.d., ph.d., executive vice president research & development and chief medical officer. read more all press releases cellectis reports financial results for 2nd quarter and first six months 2018 new york, n.y. – august 1st, 2018 – cellectis s.a. (euronext growth: alcls - nasdaq: clls), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic car t-cells (ucart), today announced its results for the three-month period ended june 30, 2018 and for the six-month period ended june 30, 2018. read more all press releases cellectis publishes novel methods to improve the clinical use of chimeric antigen receptor t-cell therapy in scientific reports june 12, 2018 – new york (n.y.) – cellectis (alternext: alcls; nasdaq: clls), a biopharmaceutical company focused on developing immunotherapies based on gene edited car t-cells (ucart), today announced the publication of a study in scientific reports , a nature publishing group journal, describing the development of the cubicar, an all-in-one chimeric antigen receptor (car) architecture with an embedded multi-functional tag for purification, detection and elimination of car t-cells. this added versatility has the potential to streamline the manufacturing of car t-cells to allow their tracking and efficiently eliminate car t-cells in clinical settings. read more all press releases fda grants cellectis ind approval for ucart22 in b-all june 4, 2018 – new york (n.y.) – cellectis (euronext growth: alcls - nasdaq: clls), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic car t-cells (ucart), announced today that the u.s. food and drug administration (fda) has approved the company’s investigational new drug (ind) application to initiate a phase 1 clinical trial for ucart22, cellectis’ second wholly controlled talen® gene-edited product candidate, for the treatment of b-cell acute lymphoblastic leukemia (b-all) in adult patients. read more all press releases press cellectis appoints stefan scherer m.d., ph.d., as senior vice president clinical development and deputy chief medical officer published on: august 02, 2018, 16:30 e.s.t. cellectis appoints stefan scherer m.d., ph.d., as senior vice president clinical development and deputy chief medical officer august 2 nd , 2018 – new york (n.y.) – cellectis (euronext growth: alcls - nasdaq: clls), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic car t-cells (ucart), announced today the appointment of dr. stefan scherer, m.d., ph.d., to the role of senior vice president clinical development and deputy chief medical officer. dr. scherer joins cellectis from novartis pharmaceuticals corporation, where he was the head of early development, strategy and innovation for u.s. oncology. dr. scherer is based in new york and will report to prof. stéphane depil, m.d., ph.d., executive vice president research & development and chief medical officer. read more all press releases cellectis reports financial results for 2nd quarter and first six months 2018 published on: august 01, 2018, 16:30 e.s.t. cellectis reports financial results for 2nd quarter and first six months 2018 new york, n.y. – august 1st, 2018 – cellectis s.a. (euronext growth: alcls - nasdaq: clls), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic car t-cells (ucart), today announced its results for the three-month period ended june 30, 2018 and for the six-month period ended june 30, 2018. read more all press releases cellectis publishes novel methods to improve the clinical use of chimeric antigen receptor t-cell therapy in scientific reports published on: june 12, 2018, 16:30 e.s.t. cellectis publishes novel methods to improve the clinical use of chimeric antigen receptor t-cell therapy in scientific reports june 12, 2018 – new york (n.y.) – cellectis (alternext: alcls; nasdaq: clls), a biopharmaceutical company focused on developing immunotherapies based on gene edited car t-cells (ucart), today announced the publication of a study in scientific reports , a nature publishing group journal, describing the development of the cubicar, an all-in-one chimeric antigen receptor (car) architecture with an embedded multi-functional tag for purification, detection and elimination of car t-cells. this added versatility has the potential to streamline the manufacturing of car t-cells to allow their tracking and efficiently eliminate car t-cells in clinical settings. read more all press releases fda grants cellectis ind approval for ucart22 in b-all published on: june 04, 2018, 16:30 e.s.t. fda grants cellectis ind approval for ucart22 in b-all june 4, 2018 – new york (n.y.) – cellectis (euronext growth: alcls - nasdaq: clls), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic car t-cells (ucart), announced today that the u.s. food and drug administration (fda) has approved the company’s investigational new drug (ind) application to initiate a phase 1 clinical trial for ucart22, cellectis’ second wholly contro

Analyse PopURL pour cellectis.com

http://www.cellectis.com/fr/investisseur/
http://www.cellectis.com/research
http://www.cellectis.com/en
http://www.cellectis.com/en/research/
http://www.cellectis.com/en/products/
http://www.cellectis.com/products/ucart/
http://www.cellectis.com/our-story/
http://www.cellectis.com/en/press/cellectis-publishes-novel-methods-to-improve-the-clinical-use-of-chimeric-antigen-receptor-t-cell-therapy-in-scientific-reports/
http://www.cellectis.com/en/about/
http://www.cellectis.com/en/press/cellectis-reports-financial-results-for-2nd-quarter-and-first-six-months-2018/
http://www.cellectis.com/en/agenda/
http://www.cellectis.com/en/legal-notice/
http://www.cellectis.com/en/careers/
http://www.cellectis.com/en/rss
http://www.cellectis.com/en/media-library/

Informations Whois

Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;

Domain Name: CELLECTIS.COM
Registry Domain ID: 14998195_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.gandi.net
Registrar URL: http://www.gandi.net
Updated Date: 2017-08-22T15:30:43Z
Creation Date: 1999-12-10T18:21:38Z
Registry Expiry Date: 2018-12-10T18:21:38Z
Registrar: Gandi SAS
Registrar IANA ID: 81
Registrar Abuse Contact Email: abuse@support.gandi.net
Registrar Abuse Contact Phone: +33.170377661
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS1.CELLECTIS.COM
Name Server: NS2.CELLECTIS.COM
Name Server: NS3.CELLECTIS.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-09-19T12:16:32Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Gandi SAS

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =cellectis.com

  PORT 43

  TYPE domain
RegrInfo
DOMAIN

  NAME cellectis.com

  CHANGED 2017-08-22

  CREATED 1999-12-10

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  NS1.CELLECTIS.COM 178.16.164.50

  NS2.CELLECTIS.COM 51.255.70.154

  NS3.CELLECTIS.COM 178.16.164.50

  REGISTERED yes

Erreurs

La liste suivante vous montre les fautes d'orthographe possibles des internautes pour le site Web recherché.